VBI Vaccines Inc. (VBIV)
NASDAQ: VBIV · IEX Real-Time Price · USD
0.557
-0.007 (-1.33%)
Apr 30, 2024, 10:08 AM EDT - Market open
VBI Vaccines Revenue
In the year 2023, VBI Vaccines had annual revenue of $8.68M with 702.40% growth. Revenue in the quarter ending December 31, 2023 was $853.00K with 191.13% year-over-year growth.
Revenue (ttm)
$8.68M
Revenue Growth
+702.40%
P/S Ratio
1.85
Revenue / Employee
$66,275
Employees
131
Market Cap
15.80M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.68M | 7.60M | 702.40% |
Dec 31, 2022 | 1.08M | 451.00K | 71.47% |
Dec 31, 2021 | 631.00K | -430.00K | -40.53% |
Dec 31, 2020 | 1.06M | -1.16M | -52.23% |
Dec 31, 2019 | 2.22M | -1.13M | -33.80% |
Dec 31, 2018 | 3.36M | 2.49M | 287.86% |
Dec 31, 2017 | 865.00K | 317.00K | 57.85% |
Dec 31, 2016 | 548.00K | -407.00K | -42.62% |
Dec 31, 2015 | 955.00K | -1.91M | -66.70% |
Dec 31, 2014 | 2.87M | 1.21M | 72.67% |
Dec 31, 2013 | 1.66M | 1.05M | 172.01% |
Mar 31, 2012 | 610.65K | 568.65K | 1,354.06% |
Mar 31, 2011 | 42.00K | 41.24K | 5,455.03% |
Mar 31, 2010 | 756.00 | -8.36K | -91.71% |
Mar 31, 2009 | 9.12K | -2.46K | -21.25% |
Mar 31, 2008 | 11.58K | -2.49K | -17.71% |
Mar 31, 2007 | 14.07K | 2.61K | 22.72% |
Mar 31, 2006 | 11.47K | 11.05K | 2,623.52% |
Mar 31, 2005 | 421.00 | 525.00 | -504.81% |
Mar 31, 2004 | -104.00 | -829.00 | -114.34% |
Mar 31, 2003 | 725.00 | -86.00 | -10.60% |
Mar 31, 2002 | 811.00 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareCloud | 117.06M |
Aytu BioPharma | 98.50M |
Meihua International Medical Technologies Co. | 97.10M |
PAVmed | 2.45M |
Talis Biomedical | 2.13M |
Avalo Therapeutics | 1.92M |
Traws Pharma | 226.00K |
VBIV News
- 14 days ago - VBI Vaccines Reports Full Year 2023 Financial Results - Business Wire
- 18 days ago - VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
- 20 days ago - VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
- 27 days ago - VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma - Business Wire
- 4 weeks ago - VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform - Business Wire
- 2 months ago - VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences - Business Wire
- 2 months ago - Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies - PRNewsWire
- 5 months ago - VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting - Business Wire